Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02713607
Other study ID # 867744
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 2016
Est. completion date January 2027

Study information

Verified date December 2023
Source University of California, Davis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lipidome and microbiome analysis in subjects with acne on doxycycline. Investigators will look at the skin lipidome, blood lipidome, gut micro biome and skin micro biome. Investigators will look at the changes between acne subjects and control participants, but also the changes that occur after the use of antibiotics and how this is altered.


Description:

We will look at acne subjects, and controls. We will look at four things 1. skin lipidome 2. skin microbiome 3. gut microbiome 4. blood lipidome Investigators will assess this in acne participants before and after doxycycline and compare them to controls.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date January 2027
Est. primary completion date January 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: - Aged 15 and older - Subjects/parents/legal guardian is able to read and comprehend study procedure and consent forms. - Have already been prescribed Doxycycline by their physician for acne or to be eligible to be prescribed Doxycycline for acne - Have acne that is diagnosed by a board certified dermatologist. Exclusion Criteria: - Those who have received systemic antibiotics within four weeks of starting the study. - Those who have received systemic isotretinoin within six weeks of starting the study. - Those with seborrheic dermatitis, rosacea, or polycystic ovary syndrome - Those who are pregnant, prisoners or cognitively impaired. - Those subjects who are currently using proton pump inhibits (as studies have shown this may impact the gut microbiome) (4) - Those who have a BMI greater than >30 kg/m2, as studies have shown a reduction in the variability of intestinal microbes within this population (5). - Those who have initiated or changed brand of oral contraceptive pill within 4 weeks of starting the study. - Those who have autoimmune disorders as this group has been shown to have an altered microbiome (6) - Those who have diabetes (6), immunodeficiencies (7), inflammatory bowel disease (6), hypercholesterolemia, as these groups have been shown to have altered gut microbiomes - Those who have taken oral probiotic supplements (8) within 4 weeks of starting the study - Given the nature of the instructions that need to be adhered to for accurate collection of samples and this data, non-English speaking individuals will be excluded from this pilot study. - Allergies to the tetracycline group of antibiotics - Those who do not fit the inclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Doxycycline
Given doxycycline to acne subjects

Locations

Country Name City State
United States UC Davis Dept of Dermatology Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Davis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the diversity of the gut microbiome in those with and without acne. The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome. 2 years
Primary Change in the diversity of the gut microbiome before and after the treatment of doxycycline in those with acne. The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome. 2 years
Secondary Change in global acne grade score 2 years
Secondary Change in the investigator global assessment of acne 2 years
Secondary Change in the lesion count of inflammatory and non-inflammatory lesions 2 years
Secondary Change in the diversity of the skin microbiome in those with and without acne The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome. 2 years
Secondary Change in the diversity of the skin microbiome before and after treatment with doxycycline in those with acne The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome. 2 years
Secondary Change in the diversity of the skin lipidome in those with and without acne The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids. 2 years
Secondary Change in the skin lipidome before and after treatment with doxycycline in those with acne The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids. 2 years
Secondary Change in the diversity of the blood lipidome in those with and without acne The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids. 2 year
Secondary Change in the blood lipidome before and after treatment with doxycycline in those with The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids. 2 years
See also
  Status Clinical Trial Phase
Completed NCT04321070 - Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris Phase 1
Recruiting NCT05755256 - The Impact of Probiotics on Skin Hydration in Youth With Mild Acne Phase 2
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT01445301 - Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects Phase 3
Completed NCT03303170 - Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris N/A
Completed NCT04698239 - Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions. N/A
Completed NCT02886715 - A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris Phase 3
Terminated NCT02924428 - Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris N/A
Not yet recruiting NCT02491060 - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Phase 3
Not yet recruiting NCT02525822 - Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris Phase 2
Not yet recruiting NCT02535871 - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Phase 3
Completed NCT02709902 - Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris Phase 1
Completed NCT02250430 - A Phase 1 Study Assessing Local Cutaneous Effects of SB204 Phase 1
Completed NCT02913001 - The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne N/A
Completed NCT01694810 - Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers Phase 1
Completed NCT01769664 - A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris Phase 1
Completed NCT01727440 - Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment N/A
Completed NCT01194375 - A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris Phase 2
Completed NCT02524665 - 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne Phase 4
Completed NCT01706250 - U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™ Phase 4